Insider Trading Alert - ALXN, SUPN And WLDN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 12, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $5,841,705.00.

Highlighted Stocks Traded by Insiders:

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Moriarty John B, who is EVP & General Counsel at Alexion Pharmaceuticals, sold 914 shares at $170.00 on June 12, 2015. Following this transaction, the EVP & General Counsel owned 32,428 shares meaning that the stake was reduced by 2.74% with the 914-share transaction.

The shares most recently traded at $170.62, up $0.62, or 0.36% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 256
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 10,344
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 55,337

The average volume for Alexion Pharmaceuticals has been 1.9 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $33.7 billion and is part of the health care sector and drugs industry. Shares are down 8.79% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 57.8. Currently, there are 15 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Supernus Pharmaceuticals (SUPN) - FREE Research Report

Schwabe Stefan K.F., who is Executive Vice President R&D at Supernus Pharmaceuticals, sold 3,631 shares at $16.39 on June 12, 2015. Following this transaction, the Executive Vice President R&D owned 4,845 shares meaning that the stake was reduced by 42.84% with the 3,631-share transaction.

The shares most recently traded at $18.26, up $1.87, or 10.23% since the insider transaction. Historical insider transactions for Supernus Pharmaceuticals go as follows:

  • 12-Week # shares sold: 2,285
  • 24-Week # shares sold: 2,285

The average volume for Supernus Pharmaceuticals has been 868,900 shares per day over the past 30 days. Supernus Pharmaceuticals has a market cap of $775.2 million and is part of the health care sector and drugs industry. Shares are up 118.07% year-to-date as of the close of trading on Friday.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has a P/E ratio of 22.5. Currently, there are 4 analysts who rate Supernus Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUPN - FREE

TheStreet Quant Ratings rates Supernus Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Supernus Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Willdan Group (WLDN) - FREE Research Report

Bieber Michael A, who is SVP, Corporate Development at Willdan Group, bought 4,000 shares at $13.95 on June 12, 2015. Following this transaction, the SVP, Corporate Development owned 4,000 shares meaning that the stake was boosted by 100% with the 4,000-share transaction.

The shares most recently traded at $13.10, down $0.85, or 6.49% since the insider transaction. Historical insider transactions for Willdan Group go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 5,000

The average volume for Willdan Group has been 91,000 shares per day over the past 30 days. Willdan Group has a market cap of $109.6 million and is part of the services sector and diversified services industry. Shares are down 2.82% year-to-date as of the close of trading on Friday.

Willdan Group, Inc., together with its subsidiaries, provides professional technical and consulting services to utilities, private industry, and public agencies at various levels of government in the Unites States. The company has a P/E ratio of 11.4. Currently, there is 1 analyst who rates Willdan Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WLDN - FREE

TheStreet Quant Ratings rates Willdan Group as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Willdan Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec